PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic Colorectal Cancer
Sponsor: Amgen
Listed as NCT00364013, this PHASE3 trial focuses on Metastatic Colorectal Cancer and remains completed. Sponsored by Amgen, it has been updated 10 times since 2006, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Sep 2018 — Sep 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.